Vascular endothelial growth factor (VEGF) has become a major target in cancer treatment as it promotes tumor angiogenesis. Therapy with anti-VEGF antibody bevacizumab reportedly induces high levels of circulating VEGF which may potentially contribute to resistance. Based on animal or computational models, mechanisms of VEGF induction by bevacizumab have… (More)
Figure 2: Expression of VEGF mRNA in liver sections of CRC metastases. Resected liver metastases from two CRC patients who were neoadjuvantly treated without bevacizumab A-C. or with bevacizumab D, E. were analyzed for VEGF mRNA expression by in situ hybridization (A, C, D). Comparable sections with hematoxylin and eosin staining (B, E) are shown. The location of tumor cells (T), stromal cells (S) and hepatocytes (H) is indicated. F. Plasma VEGF levels of these two patients at the time of surgery.